Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Globe Newswire•13/10/2026•19:30 ET
1
Key Highlights
- ➤IMCIVREE commercial launch begins in Japan for acquired hypothalamic obesity
- ➤IMCIVREE becomes Japan’s first approved therapy for acquired hypothalamic obesity
- ➤Japan’s MHLW added IMCIVREE to the National Health Insurance drug price list
- ➤Phase 3 TRANSCEND showed 18.8% placebo-adjusted BMI reduction
- ➤Rhythm estimates Japan’s acquired hypothalamic obesity population at 5,000 to 8,000
Expert Statements
Yann Mazabraud, Executive Vice President and Head of International at Rhythm Pharmaceuticals
“This launch marks an important advancement for people living with acquired HO in Japan where there were no approved therapies for this disease until now”
Yann Mazabraud, Executive Vice President and Head of International at Rhythm Pharmaceuticals
“We have been building our team in Japan in preparation for this launch and are excited about the opportunity to positively impact the lives of Japanese patients. This is a significant milestone in our global efforts to bring innovative therapies to patients with rare neuroendocrine diseases around the world.”
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list --
-- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --
Get started
Create a free account to read the full story.